Drug Discovery World
APRIL 3, 2023
As a business of scientists, we remain passionate about the exciting developments in the industry, from research to precision therapies, and insatiably curious about the new possibilities that can be achieved by overcoming the limits of standard research tools and methods. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley.
XTalks
OCTOBER 1, 2020
Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 30, 2023
coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents. DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. GSK has developed high-throughput mammalian and E.
Drug Discovery World
DECEMBER 13, 2023
Moreover, custom antibodies are a key reagent in companion diagnostics for these novel therapeutics. Custom antibodies can be developed for pharmacokinetic assays and biodistribution assays, supporting therapeutic development by giving researchers data about the behaviour of their novel therapeutic in vivo.
XTalks
APRIL 22, 2022
Receptor occupancy assays have been developed and applied in both nonclinical and clinical studies to provide insight into PK/PD relationships so far,” said Andre Olsson, PhD, Senior Scientist, Flow Cytometry at the global contract research organization (CRO) Medpace. What is Flow Cytometry?
Drug Discovery World
FEBRUARY 15, 2023
Sophisticated and continually evolving preclinical IO models (in vivo and in vitro) are particularly helpful in defining translational therapeutic strategies and understanding the efficacy of combination immunotherapies and refractory cancers, and in the identification of novel prognostic biomarkers. This continues to be the standard of care.
Drug Discovery World
JULY 18, 2023
Incorporating in vivo pooled CRISPR screens has allowed for the interrogation of thousands of genetic perturbations in cells, leading to the determination of the involvement of molecules (PTPN2, ADAR1, or DHX37) in immune checkpoint inhibitor (ICI) responsiveness and T cell activation.
Expert insights. Personalized for you.
52 
Let's personalize your content